Theravance Biopharma Inc expected to post a loss of 21 cents a share - Earnings Preview

Theravance Biopharma

03/08/2024 24:28

* Theravance Biopharma Inc  TBPH.OQ   TBPH.O  is expected
to show
a rise in quarterly revenue when it reports  results on August 5
for the period ending March 31 2024
    * The George Town Grand Cayman-based  company is expected to
report a 12.4% increase in revenue to $15.453 million from
$13.75 million a year ago, according to the mean estimate from 4
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Theravance Biopharma Inc
is
for a loss of 21 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Theravance
Biopharma Inc is $15.00​, above​ its last closing price
of $9.64. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001               -0.25      -0.24     Beat    
 Jan. 1 0001               -0.15      -0.17     Missed  -14.3
 Jan. 1 0001   -0.22                  -0.17             ​
 Jun. 30 2023  -0.22       -0.21      -0.35     Missed  -33.3
 ​​Mar.        -0.25       -0.25      -0.35     Missed  -42.1
 31 2023                                                
 Jan. 1 0001   -0.17       -0.17      -0.15     Beat    13​
 Sep. 30 2022  -0.21       -0.18      -0.21     Missed  -15.1
 Jan. 1 0001   0.09        0.11       -0.09     Missed  -182.6
 This summary was machine generated August 2 at 23:28 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)